https://charts.traderzeitung.de/phases/GB00BMVP7Y09
string(1497) "{"isin":"GB00BMVP7Y09","name":"Royalty Pharma PLC","stock_id_xnas":13580378,"stock_id_xnys":null,"generated_at":"2026-08-09 08:05:00","days":[{"date":"2026-08-05","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":59.09,"close_at":"2026-08-05 15:27:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":57.72,"close_at":"2026-08-05 21:59:00","complete":true,"perf_pct":-2.3185},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":57.87,"close_at":"2026-08-05 22:01:00","complete":true,"perf_pct":0.2599}]},{"date":"2026-08-06","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":58.99,"close_at":"2026-08-06 15:28:00","complete":true,"perf_pct":1.9354},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":57.245,"close_at":"2026-08-06 21:59:00","complete":true,"perf_pct":-2.9581},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":57.4,"close_at":"2026-08-07 00:41:00","complete":true,"perf_pct":0.2708}]},{"date":"2026-08-07","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":57.92,"close_at":"2026-08-07 15:25:00","complete":true,"perf_pct":0.9059},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":56.79,"close_at":"2026-08-07 21:59:00","complete":true,"perf_pct":-1.951},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Royalty Pharma Aktie News & Nachrichten
Trading-Room

Royalty Pharma Aktie News & Nachrichten

[WKN: A2P62D | Symbol: RPRX]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel
Trader-Zeitung Agents
Agentische Berichterstattung zu Royalty Pharma

Artikel aus der Redaktion der Trader-Zeitung

Royalty Pharma

TOP-5-Kursziele der Analysten am 16.05.25

Birkenstock [JE00BS44BN30]: UBS bekräftigt Buy-Rating und erhöht das Kursziel von 72 auf 76 USD (32...

  • ‹
  • 1
  • ›
Royalty Pharma Nachrichtenticker öffnen
MT Newswires 05.08.2026 13:33 Uhr

Royalty Pharma verzeichnet sinkenden Nettogewinn, aber steigenden Umsatz im Q2

07:25 AM EDT, 08/05/2026 (MT Newswires) -- Royalty Pharma (RPRX) meldete am Mittwoch für das Q2 einen Nettogewinn von 18 Millionen US-Dollar, verglich

MT Newswires 05.08.2026 13:09 Uhr

-- Earnings Flash (RPRX) Royalty Pharma plc meldet Q2-Umsatz von 674,0 Mio. USD

07:00 AM EDT, 05.08.2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 22.07.2026 15:19 Uhr

Branchenupdate: Gesundheitsaktien tendieren am Mittwoch vorbörslich leicht höher

09:18 AM EDT, 22.07.2026 (MT Newswires) -- Gesundheitsaktien tendierten am Mittwoch vorbörslich leicht höher, wobei der State Street Health Care Selec

MT Newswires 22.07.2026 13:38 Uhr

Research-Alert: Royalty Pharma erwirbt Lizenzgebührenanteil an Cliramitug von AstraZeneca

07:37 AM EDT, 22.07.2026 (MT Newswires) -- Royalty Pharma (RPRX) teilte am Mittwoch mit, dass das Unternehmen bis zu 425 Millionen US-Dollar, einschli

MT Newswires 17.07.2026 22:24 Uhr

Royalty Pharma behält vierteljährliche Dividende von 0,235 $ pro Aktie bei, zahlbar am 10. Sept. an die am 14. Aug. eingetragenen Aktionäre

04:23 PM EDT, 17.07.2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 25.06.2026 23:19 Uhr

Royalty Pharma Insider hat Aktien im Wert von $8.159.277 verkauft, laut einer aktuellen SEC-Einreichung

05:18 PM EDT, 06/25/2026 (MT Newswires) -- Christopher Hite, Executive Vice President & Chairman, Partnering, hat am 23. Juni 2026 150.000 Aktien

MT Newswires 25.06.2026 23:18 Uhr

Royalty Pharma Insider verkaufte Aktien im Wert von $502.067, laut einer aktuellen SEC-Einreichung

05:17 PM EDT, 06/25/2026 (MT Newswires) -- Marshall Urist, Executive Vice President, Research & Investments, verkaufte am 24. Juni 2026 9.098 Akti

MT Newswires 28.05.2026 22:54 Uhr

Royalty Pharma Insider verkaufte Aktien im Wert von $3.476.116, laut einer aktuellen SEC-Einreichung

04:53 PM EDT, 05/28/2026 (MT Newswires) -- Terrance P. Coyne, Executive Vice President & CFO, verkaufte am 26. Mai 2026 64.399 Aktien von Royalty